Tanibirumab (TTAC-0001): A Fully Human Monoclonal Antibody Targets Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2)

被引：29
作者：
Lee, Sang Hoon [1 ]
机构：
[1] PharmAbcine, Taejon 305811, South Korea
来源：
ARCHIVES OF PHARMACAL RESEARCH | 2011年 / 34卷 / 08期
关键词：
TUMOR ANGIOGENESIS; THERAPY; DISEASE;
D O I：
10.1007/s12272-011-0821-9
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Vascular endothelial growth factor (VEGF) binds to its receptor (VEGFR) and stimulates angiogenesis, an important step in tumor growth and metastasis. Several anticancer therapies targeting VEGFR with small molecules and antibody have been currently studied in preclinical and clinical studies. This article provides a review of human monoclonal antibody tanibirumab (TTAC-0001), which specifically binds VEGFR-2 and is currently being developed in preclinical stage by PharmAbcine (Daejon, Korea).
引用
收藏
页码：1223 / 1226
页数：4
相关论文
共 16 条
[11]   Vascular growth factors and lymphangiogenesis [J].
Jussila, L ;
Alitalo, K .
PHYSIOLOGICAL REVIEWS, 2002, 82 (03) :673-700
[12]   Lymphatic endothelium:: a new frontier of metastasis research [J].
Karkkainen, MJ ;
Mäkinen, T ;
Alitalo, K .
NATURE CELL BIOLOGY, 2002, 4 (01) :E2-E5
[13]   Tumor angiogenesis: past, present and the near future [J].
Kerbel, RS .
CARCINOGENESIS, 2000, 21 (03) :505-515
[14]   Vascular and haematopoietic stem cells:: Novel targets for anti-angiogenesis therapy? [J].
Rafii, S ;
Lyden, D ;
Benezra, R ;
Hattorï, K ;
Heissig, B .
NATURE REVIEWS CANCER, 2002, 2 (11) :826-835
[15]   Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2 [J].
Spratlin, Jennifer .
CURRENT ONCOLOGY REPORTS, 2011, 13 (02) :97-102
[16]  
Spratlin JL, 2010, FUTURE ONCOL, V6, P1085, DOI [10.2217/fon.10.75, 10.2217/FON.10.75]
12